Bovie Medical Corporation Acquires Technology, Patents and Assets From Boston Scientific for RF Resection Device
Posted on: Thursday, 1 May 2008, 09:01 CDT
Bovie Medical Corporation (the "Company") (Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced it has signed an agreement with Boston Scientific Corporation (NYSE: BSX) to acquire technology, patents, and assets related to the use of conductive sintered steel as an electrode for radio frequency (RF) cutting and coagulation, intended to lower blood loss, quicken procedure times and provide cost savings for hospitals. Potential fields of therapy for the technology acquired include liver, pancreatic and kidney tumor therapies along with orthopedic and blood vessel sealing. The process involves delivery of RF current and sterile saline for resection, hemostatic sealing and coagulation in open and laparoscopic surgery. The worldwide market size for the liver and orthopedic market is expected to total $500 million in 2009.
This agreement replaces a previously signed distribution and marketing agreement between the Companies for the technology's use in Boston Scientifics' oncology business. The original development and manufacturing agreement signed in 2007 required Bovie to develop and manufacture certain products using Boston Scientifics' intellectual property. Bovie intends to finalize the development and commercialization of the technology. As part of the agreement, Bovie granted a license to Boston Scientific limited until 2016 to uses outside of those fields listed above.
Andrew Makrides, president of Bovie Medical Corporation commented, "This agreement further enhances Bovie's intellectual property portfolio, while creating new significant market opportunities for the Company. Adding strength to Bovie's new product line, Mr. Bob Rioux, who was at the forefront of the Boston Scientific tissue resection program, is joining Bovie as Vice President of Advanced Resection Technologies. Mr. Rioux's combination of technical and marketing skills makes him ideally suited to commercialize these new products."
Mr. Makrides concluded, "With the expected launch of the MEG line in Europe, management's goal of transforming Bovie into a leading technology medical device company has commenced. While these initiatives may, in the short term, impact our bottom line, management believes we are building a solid foundation for increasing shareholder value."
This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company's SEC filings. www.boviemedical.com
Source: Business Wire
Related Articles
- Milestone Scientific Signs Supply and Distribution Agreement with Utah Medical Products for CompuMed(R)
- Invitrogen Signs US Distribution Agreement With Biocare Medical
- Spiration, Inc. Signs Agreement With Olympus Medical Systems for Development and Distribution Rights of Minimally Invasive Pulmonary Device Therapy in Japan
- LifeStem Signs Joint Venture Agreement With Keller Medical Institute
- Xenomis LLC Signs Licensing Agreement With Harvard Medical School For Technology to Assist in the Development of Nutraceutical Products Based Upon Proprietary Stressed Plant Science
- Cardinal Health Signs Exclusive Agreement With HemCon Medical Technologies, Inc. To Distribute Hemorrhage Control Bandages in U.S.
- Analogic Corporation Signs Agreement With Sphere Medical to Develop Innovative Glucose Monitor for Critical Care Market
- Unisource Signs Agreement With IBM to Market and Distribute IBM Branded Papers
- Aphios Corporation Announces Licensing of Non-Toxic Vitamin D Analog for Prostate Cancer From Boston University Medical School
- PAREXEL Appoints Glenn C. Van Deusen As Corporate Vice President and General Manager of Medical Marketing Services
 |
 |
User Comments (0)
RSS Feeds